METTL3 and neoplasm: For example, despite the emerging m6A-associated targets of therapeutic value have been identified in different types of infiltrated immune cells, and METTL3 has been widely verified to deeply impact tumor biology and TME harmony as the predominant catalytic subunit of m6A writer complex [117, 173, 174, 200, 201], only several small molecules targeting m6A-associated enzymes were evaluated in some preclinical trials [125, 186].